Loading…
Artiva Biotherapeutics Inc Is A Biopharmaceutical Company. The Company Is Engaged In Advancing A Pipeline Of Off-The-Shelf, Allogeneic Nk Cell Therapies For The Treatment Of Hematologic Malignancies Or Solid Tumors. The Pipeline Program Of The Company Includes Artiva-Funded Trials And Collaborator-Funded Trials. The Company Pipeline Includes Allonk: Is An Allogeneic, Off-The-Shelf, Cryopreserved Nk Cell Therapy Candidate Designed To Enhance The Antibody-Dependent Cellular Cytotoxicity (Adcc) Effect Of Mabs To Drive B-Cell. Others Products Includes: Car-Nk(Ab201),Car-Nk(Ab205).